VYNE Therapeutics (VYNE) Financials

$28.56

$3.11 (12.22%)

As on 27-Jul-2026 16:00EDT

Market cap

$19 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	0.96	0.57	0.50	0.42	0.48	0.93
Cost of Revenue	0.02	0.02	0.00	--	--	3.35
Gross Profit	0.95	0.55	0.50	0.42	0.48	0.93
Operating Expenses	47.53	30.30	44.14	29.68	34.77	39.84
Operating Profit (EBIT)	-46.58	-29.75	-43.64	-29.26	-34.30	-38.91
Other Income	--	--	--	--	--	--
Profit before Tax	-42.70	-26.73	-39.80	-27.87	-33.93	-43.76
Provision for Tax	-0.14	0.00	0.00	0.58	0.01	0.45
Profit after Tax (Net Income)	-42.19	-26.48	-39.83	-28.45	-23.21	-73.33
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-23.21	-73.33

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	0.03	27.77	52.09	88.74	31.20	48.64
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	--	--	1.41	0.21	6.86
Current Liabilities	0.00	2.40	14.82	7.54	9.35	18.41
Total Liabilities	0.03	30.16	66.91	97.69	40.76	67.05

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	0.00	0.15	2.47	1.72	2.48	3.86
Current Assets	0.03	30.01	64.44	95.96	38.28	63.19
Total Assets	0.06	30.16	66.91	97.69	40.76	67.05
Total Debt*	--	--	0.10	0.21	0.35	0.35
Net Current Assets	--	27.62	49.62	88.43	28.93	44.78

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-33.12	-33.97	-25.34	-29.20	-56.37
Cash Flow from Investing Activities	--	37.37	23.37	-57.35	15.67	1.03
Cash from Financing Activities	--	-0.14	-0.14	82.39	1.65	39.78
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-637.12	-30.96	-46.76	-9.16	-7.78	-1,232.42
Cash EPS ($)	--	-30.93	-46.76	-9.21	-7.75	-1,230.59
Adjusted Book Value ($)	--	32.46	61.15	28.58	10.45	817.41
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-38.72	-39.88	-8.16	-9.78	-947.34
Free Cash Flow per Share ($)	--	-38.72	-40.02	-8.16	-9.78	-947.34

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-66.25	-56.45	-47.22	-57.64	-120.94
ROE (%)	-303.57	-66.33	-56.57	-47.44	-58.14	-170.28
ROA (%)	-166.69	-54.57	-48.40	-41.10	-43.06	-91.21
EBIT Margin (%)	-1,671.94	--	-7,944.71	-6,840.33	-7,113.63	-4,097.74
Net Margin (%)	-4,417.28	-4,646.14	-7,950.90	-6,710.38	-4,865.83	-7,876.37
Cash Profit Margin (%)	-0.26	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	100.63	0.14	0.18	-0.11	-0.49	-0.96
EBIT Growth (%)	41.13	--	-37.24	14.53	11.06	84.83
Net Profit Growth (%)	-9.44	33.52	-40.00	-22.59	68.35	71.31
EPS Growth (%)	-1,309.38	0.34	-4.10	-0.18	0.99	0.74
Book Value Growth (%)	-98.57	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.02	-0.07	-0.25	-0.02	0.00
Price / Book Value	0.75	0.02	0.05	0.08	0.01	0.00
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	1.84	1.07	1.47	3.08	0.89	1.10
Close Price ($)	32.54	29.01	167.50	116.50	135.00	918.00
High Price ($)	98.00	215.00	171.50	436.50	1,062.00	11,880.00
Low Price ($)	14.03	14.03	79.50	109.10	99.63	810.00
Market Cap ($ Cr)	19.07	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	--	0.00	0.00	0.01	0.01
Short term debt to equity ratio	--	--	0.00	0.00	--	0.01
Current Ratio	12.53	12.53	4.35	12.73	4.10	3.43
Quick Ratio	12.53	--	--	--	4.09	3.04
Interest Coverage	--	--	--	--	-3.14	-6.80

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	1,084.49	814.50
Asset Turnover	0.04	0.01	0.01	0.01	0.01	0.01
Receivable days	--	--	--	4,456.22	4,883.78	4,590.54
Inventory Days	--	--	--	--	--	801.58
Payable days	--	29,759.93	199,335.19	--	--	615.84
Cash Conversion Cycle	--	--	--	--	--	4,776.27

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.